Objective Patients with autoimmune or inflammatory disease (AID) are susceptible to
immune-related adverse events (irAEs) when treated with immune check-point inhibitors (ICIs). We …

The anti-tumour and anti-metastatic properties of heparins have not been tested in patients
with early stage cancer. Whether adjuvant low molecular weight heparin (LMWH) tinzaparin …

Purpose To determine, by using contrast material–enhanced ultrasonography (US), how
quickly renal tumors grafted in mice begin to revascularize after stopping bevacizumab …

BACKGROUND: Preliminary results indicated that bortezomib (B) (Velcade*) as a single agent
may have activity in pretreated NSCLC patients with similar or lesser toxicity compared to …

Medical elastography consists of biomechanically characterising a zone of tissue on the
basis of its response to the application of mechanical stress. This stress can be quasistatic (local …

Nivolumab for the treatment of advanced nonsmall cell lung cancer (NSCLC) evaluated in
phase III trials showed 50% progression at first evaluation, but better overall survival (OS), …

6 Wulff C, Wilson H, Rudge JS, et al. Luteal angiogenesis: prevention and intervention by
treatment with vascular endothelial growth factor trap (A40). J Clin Endocrinol Metab 2001; …

Physicians who are responsible for the delivery of systemic treatment in lung cancer should
be aware of the potential risk of drug‐induced pulmonary toxicity (DIPT), because such …

L’évolution des connaissances biologiques dans le cancer du rein depuis 20 ans a révélé
le rôle fondamental de l’angiogenèse dans la physiopathologie du cancer du rein. Les …

Background Small-cell lung cancer (SCLC) accounts for approximately 15% of lung cancer
and is associated with poor prognosis. In platinum-refractory or -resistant SCLC patients, few …